A Case Report on the Dramatic Response of ¹⁷⁷Lu-PSMA Therapy for Metastatic Prostate Cancer.

IF 1.1 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Current Medical Imaging Reviews Pub Date : 2025-01-01 DOI:10.2174/0115734056362468250709045212

Aysenur Sinem Erdogan, Haluk Sayan, Bedri Seven, Berna Okudan

{"title":"A Case Report on the Dramatic Response of 177Lu-PSMA Therapy for Metastatic Prostate Cancer.","authors":"Aysenur Sinem Erdogan, Haluk Sayan, Bedri Seven, Berna Okudan","doi":"10.2174/0115734056362468250709045212","DOIUrl":null,"url":null,"abstract":"Introduction: In nuclear medicine, Prostate-specific Membrane Antigen (PSMA) is a potential target for theranostics. Offering superior diagnostic accuracy to conventional imaging in prostate cancer (PCa), Gallium-68 labeled PSMA (68Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is considered the new standard of care in PCa management. Tumor cells identified as PSMA-avid on PET/CT imaging can be targeted and eliminated with PSMA-labeled Lutetium-177 (177Lu-PSMA) therapy.Case presentation: A sixty-eight years old patient who had metastatic castration-resistant PCa was reported in this study. Prior to receiving 177Lu-PSMA therapy, the patient's PSA level was 358 ng/ml, and experienced extensive bone discomfort. Following ten cycles of 177Lu-PSMA therapy, exceptional results were observed.Conclusion: 177Lu-PSMA therapy is likely to result in significantly better outcomes if first- or second-line treatments preserve the patient's bone marrow reserve or if the therapy is administered at earlier stages of the disease.","PeriodicalId":54215,"journal":{"name":"Current Medical Imaging Reviews","volume":" ","pages":"e15734056362468"},"PeriodicalIF":1.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Medical Imaging Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115734056362468250709045212","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In nuclear medicine, Prostate-specific Membrane Antigen (PSMA) is a potential target for theranostics. Offering superior diagnostic accuracy to conventional imaging in prostate cancer (PCa), Gallium-68 labeled PSMA (⁶⁸Ga-PSMA) positron emission tomography/computed tomography (PET/CT) is considered the new standard of care in PCa management. Tumor cells identified as PSMA-avid on PET/CT imaging can be targeted and eliminated with PSMA-labeled Lutetium-177 (¹⁷⁷Lu-PSMA) therapy.

Case presentation: A sixty-eight years old patient who had metastatic castration-resistant PCa was reported in this study. Prior to receiving ¹⁷⁷Lu-PSMA therapy, the patient's PSA level was 358 ng/ml, and experienced extensive bone discomfort. Following ten cycles of ¹⁷⁷Lu-PSMA therapy, exceptional results were observed.

Conclusion: ¹⁷⁷Lu-PSMA therapy is likely to result in significantly better outcomes if first- or second-line treatments preserve the patient's bone marrow reserve or if the therapy is administered at earlier stages of the disease.

查看原文本刊更多论文

177Lu-PSMA治疗转移性前列腺癌的显著反应一例报告。

在核医学中，前列腺特异性膜抗原（PSMA）是一个潜在的治疗靶点。镓-68标记PSMA （68Ga-PSMA）正电子发射断层扫描/计算机断层扫描（PET/CT）被认为是前列腺癌治疗的新标准，比传统影像学诊断前列腺癌（PCa）的准确性更高。在PET/CT成像上鉴定为PSMA-avid的肿瘤细胞可以通过psma标记的Lutetium-177 （177Lu-PSMA）治疗来靶向和消除。病例介绍：本研究报告了一位68岁的转移性去势抵抗性前列腺癌患者。在接受177Lu-PSMA治疗之前，患者的PSA水平为358 ng/ml，并经历了广泛的骨骼不适。经过10个周期的177Lu-PSMA治疗，观察到异常的结果。结论：如果一线或二线治疗能够保留患者的骨髓储备，或者在疾病的早期阶段进行治疗，那么lu - psma治疗可能会产生明显更好的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Medical Imaging Reviews 医学-核医学

CiteScore

2.60

自引率

0.00%

发文量

246

审稿时长

1 months

期刊介绍： Current Medical Imaging Reviews publishes frontier review articles, original research articles, drug clinical trial studies and guest edited thematic issues on all the latest advances on medical imaging dedicated to clinical research. All relevant areas are covered by the journal, including advances in the diagnosis, instrumentation and therapeutic applications related to all modern medical imaging techniques. The journal is essential reading for all clinicians and researchers involved in medical imaging and diagnosis.